Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Summit Therapeutics said its partner Akeso announced updated clinical data, including overall-survival results. The provided article text does not include the trial outcomes, patient population, or numerical efficacy and safety data needed to assess the announcement's financial or clinical significance.